Molecular structure of Aurora Kinase Inhibitor III, CAS Number: 879127-16-9
Aurora Kinase Inhibitor III (CAS 879127-16-9)
Alternate Names:
Cyclopropanecarboxylic acid-(3-(4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino)-phenyl)-amide
Application:
Aurora Kinase Inhibitor III is an ATP-competitive potent inhibitor of ARK-1
CAS Number:
879127-16-9
Purity:
>95%
Molecular Weight:
413.4
Molecular Formula:
C21H18F3N5O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Aurora kinase inhibitor III is a potent ATP-competitive aurora related kinase (also designated ARK) inhibitor. Aurora kinase inhibitor III is a cell-permeable, 2,4-dianilinopyrimidine compound which has been used to study a variety of tumor types. Aurora kinase protein levels are elevated in c-myc-driven B-cell lymphomas in both mice and humans; study of the inhibition of Aurora kinase proteins could lead to potential treatments for malignancies.
Aurora Kinase Inhibitor III (CAS 879127-16-9) References
- Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. | Zhang, Q., et al. 2006. J Am Chem Soc. 128: 2182-3. PMID: 16478150
- A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | Fedorov, O., et al. 2007. Proc Natl Acad Sci U S A. 104: 20523-8. PMID: 18077363
- ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. | Thollet, A., et al. 2010. Mol Cancer. 9: 291. PMID: 21059223
- WD40-repeat protein 62 is a JNK-phosphorylated spindle pole protein required for spindle maintenance and timely mitotic progression. | Bogoyevitch, MA., et al. 2012. J Cell Sci. 125: 5096-109. PMID: 22899712
- Kinase inhibitor profile for human nek1, nek6, and nek7 and analysis of the structural basis for inhibitor specificity. | Moraes, EC., et al. 2015. Molecules. 20: 1176-91. PMID: 25591119
- Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. | Mashima, T., et al. 2015. Cancer Sci. 106: 909-20. PMID: 25911996
- JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. | Nishiya, N., et al. 2015. World J Biol Chem. 6: 409-18. PMID: 26629323
- Targeting the ataxia telangiectasia mutated pathway for effective therapy against hirsutine-resistant breast cancer cells. | Lou, C., et al. 2016. Oncol Lett. 12: 295-300. PMID: 27347141
- Protein kinase D1 (PKD1) phosphorylation on Ser203 by type I p21-activated kinase (PAK) regulates PKD1 localization. | Chang, JK., et al. 2017. J Biol Chem. 292: 9523-9539. PMID: 28408623
- A kinase inhibitor screen identifies signaling pathways regulating mucosal growth during otitis media. | Noel, J., et al. 2020. PLoS One. 15: e0235634. PMID: 32760078
Inhibitor of:
ARK-1, and Ser/Thr Protein Kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aurora Kinase Inhibitor III, 1 mg | sc-203828 | 1 mg | $186.00 |